Max Healthcare Institute LtdNSE: MAXHEALTH
Open the Max Healthcare Institute Ltd page
Follow Max Healthcare Institute LtdFree account. Get a note when Max Healthcare Institute Ltd files.
Q1 FY27 results analysis · August 14, 2026

Max Healthcare Institute Ltd (MAXHEALTH) Q1 FY27 Results Analysis: EBITDA Margin Compresses 301 bps, Revenue Grows 16.7%

+4.9%PAT year on year, Rs. 322.96 Cr
Cofacto ResearchPublished August 14, 20262 min readNeutral read
Quick summary

Max Healthcare Institute Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 2,366.17 Cr (+16.70% YoY) and PAT growth of +4.87% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 13, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 2,366.17 Cr (+16.70% YoY)
PAT (Q1)Rs. 322.96 Cr (+4.87% YoY)
EBITDA margin25.29% (-50 bps YoY)
EPS (Q1)Rs. 3.32 (+4.73% YoY)
Market capRs. 98,618.79 Cr
CMPRs. 1,013.30

Quarter Snapshot

Revenue grew 16.7% YoY with strong occupancy and CGHS tailwind, but EBITDA margin compressed 301 bps QoQ as doctor costs and new tower ramp-up costs outpaced growth. PAT rose only 4.87% due to cost escalation, higher depreciation/finance costs, and an elevated tax rate. The quarter is a building quarter with margin recovery expected as new beds fill and CGHS benefit annualises.

Key Investment Insights

Key Positives

  • Revenue from operations grew 16.7% YoY to Rs.2,366.17 Cr, driven by CGHS rate revision, new bed additions, and Kalinga acquisition.
  • Consolidated occupancy remained above 75%, indicating high asset utilisation.
  • Subsidiary contribution to PAT grew 9.1% YoY to Rs.154.89 Cr, reflecting strong network performance.
  • CGHS rate revision (full super-specialty rates) effective from April 1, 2026, is a structural tailwind.
  • Bed count reached 6,100+ vs ~6,000 at end FY26, with pipeline to ~6,500 by FY27 end.
  • Board approved Rs.425 Cr capex for Tower 3 at Vaishali, expanding bed capacity.
  • Kalinga acquisition completed and integrated; YPPL Pune first tranche completed.
  • CCI case closed with no adverse order (May 22, 2026).

Risk Factors

  • EBITDA margin declined 301 bps QoQ (to 25.29%) and 50 bps YoY due to cost pressures and new tower costs not yet absorbed.
  • Professional and consultancy fees (doctor costs) grew 22.76% YoY, outpacing revenue growth of 16.7%, pushing cost ratio to 22.12% of revenue.
  • PAT growth of 4.87% YoY significantly lagged revenue growth of 16.7%, reflecting margin compression and higher tax rate.
  • Effective tax rate increased to 25.98% from 23.09% YoY, a 290 bps headwind to PAT.
  • Finance costs rose 29.44% YoY and depreciation 26.43% YoY due to capex and acquisition financing, pressuring bottom line.
  • Standalone EBITDA declined 2.79% YoY, indicating weaker performance at the holding level compared to consolidated subsidiaries.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.